OptiBiotix Health PLC LPLDL® Exclusive European License Agreement (7490G)
March 06 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 7490G
OptiBiotix Health PLC
06 March 2018
6 March 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
LP(LDL) (R) Exclusive European License Agreement
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it has entered into a production and
commercialisation agreement with Fine Foods & Pharmaceuticals
N.T.M. S.p.A ("Fine Foods"). The agreement grants Fine Foods an
exclusive license for the production and supply of five
formulations containing OptiBiotix's LP(LDL) (R) strain in Europe
in return for royalty payments and a commitment to maximising the
financial return for both parties.
Fine Foods is based in Italy and has more than 30 years'
experience in the design, development and manufacture of customised
formulations and presentations for the pharmaceutical and food
supplement industry. With revenues of EUR120m in 2017, it is one of
Europe's largest and fastest growing providers of food supplements
and pharmaceutical products, with full GMP certified production
facilities and leading pharmaceutical companies such as Pfizer,
Bayer, Sanofi etc reported as customers on its website.
Fine Foods has an international reputation and world leading
expertise in developing unique formulations and presentations
containing probiotic strains. Under the terms of the agreement,
Fine Foods have an exclusive license to produce and commercialise
five new formulations containing OptiBiotix's LP(LDL) (R) . One for
glucose control, one for reduction of high blood pressure, one for
reduction of cholesterol levels and two for the reduction of
cardiovascular risk. These proprietary formulations will be
marketed in innovative presentations including sachets and 'melt in
the mouth' sticks, to their extensive European network in both the
pharmaceutical and food supplement industry.
This agreement is another step in a business to business (B2B)
strategy of bringing OptiBiotix's science together with partner's
expertise and market reach to create multiple product opportunities
to serve consumer healthcare and pharmaceutical markets around the
world.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce this exclusive license agreement with Fine Foods for the
production and commercialisation of five new proprietary
formulations containing OptiBiotix's LP(LDL) (R) . This agreement
extends the range of products and presentations containing
OptiBiotix's LP(LDL) (R) and creates an opportunity to access
global pharmaceutical markets with an established industry
supplier. We chose Fine Foods due to its industry experience,
reputation, rapid revenue growth, and impressive client list of
global customers in both the Pharmaceutical and Food Supplement
sectors. We believe our strategy of identifying and building
partnerships with industry leading partners like Fine Foods,
provides the best opportunity of rapidly building revenue streams,
and establishing LP(LDL) (R) as a leading global brand."
Giorgio Ferraris, CEO of Fine Foods, commented: "We are very
excited to enter this agreement with OptiBiotix, which will allow
us to promote specific formulations and presentations containing
the innovative OptiBiotix's LP(LDL) (R) strain to customers active
in the growing market segment of Cholesterol and Blood pressure
reduction, as well as Cardiovascular risk. We believe this a unique
opportunity for us to expand our commercial presence in the
European Food Supplement industry, and has the potential to
favourably enhance our existing rate of growth over the coming
years."
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
Article 7 of Regulation (EU) No 596/2014 (MAR).
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRJAMFTMBAMBTP
(END) Dow Jones Newswires
March 06, 2018 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024